Spyre Therapeutics (SYRE) Research & Development (2015 - 2026)

Spyre Therapeutics has reported Research & Development for 12 years, with the latest figure at $60.4 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 45.14% year-over-year to $60.4 million; the trailing twelve-month figure through Mar 2026 stood at $190.4 million (up 12.36% YoY), and the FY2025 full-year result was $171.7 million, up 5.44% from the prior year.
• Research & Development for Q1 2026 stood at $60.4 million, up from $44.6 million in the prior quarter.
• The five-year high for Research & Development was $60.4 million in Q1 2026, with the low at $12.0 million in Q3 2022.
• Historically, Research & Development has averaged $31.9 million across 5 years, with a median of $33.7 million in 2023.
• Annual changes were most pronounced in 2022 — Research & Development fell 19.36% — and 2024, when it surged 153.54%.
• Spyre Therapeutics' Research & Development stood at $14.3 million in 2022, then soared by 136.35% to $33.7 million in 2023, then soared by 49.88% to $50.5 million in 2024, then decreased by 11.58% to $44.6 million in 2025, then jumped by 35.34% to $60.4 million in 2026.
• The last three Research & Development figures came in at $60.4 million (Q1 2026), $44.6 million (Q4 2025), and $45.2 million (Q3 2025), per Business Quant data.